1h Free Analyst Time
The migraine drugs market in latin america is forecasted to grow by USD 80 million during 2023-2028, accelerating at a CAGR of 5.4% during the forecast period. The report on the migraine drugs market in latin america provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of migraine in latin america, growing number of migraine treatment awareness programs, and drug reformulations strengthening vendor portfolios.
The migraine drugs market in latin america is segmented as below:
By End-user
- Hospitals
- Retail
- Online
By Geographical Landscape
- Latin America
By Therapy
- Preventive treatment
- Abortive treatment
The report on the migraine drugs market in latin america covers the following areas:
- Migraine drugs market in latin america sizing
- Migraine drugs market in latin america forecast
- Migraine drugs market in latin america industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Therapy
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the migraine drugs market in Latin America: AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, Daiichi Sankyo Co. Ltd., DR Reddys Laboratories Ltd., Eli Lilly and Co., Endo International PLC, Ethypharm SAS, GlaxoSmithKline PLC, H Lundbeck AS, IntelGenx Technologies Corp., Klaria Pharma Holding AB, Kowa Co. Ltd., OptiNose Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and UCB SA.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is introduction of new classes of drugs with higher clinical efficacy."
According to the report, one of the major drivers for this market is the increasing prevalence of migraine in Latin America.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- Amneal Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Bayer AG
- Daiichi Sankyo Co. Ltd.
- Dr Reddys Laboratories Ltd.
- Eli Lilly and Co.
- Endo International Plc
- Ethypharm SAS
- GlaxoSmithKline Plc
- H Lundbeck AS
- IntelGenx Technologies Corp.
- Klaria Pharma Holding AB
- Kowa Co. Ltd.
- OptiNose Inc.
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- UCB SA
